Immunovant Inc — Cash Flow (NASDAQ:IMVT) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics

Quarterly Annual

Cash from operating activities -83.33 M-106.11 M-188.19 M-214.23 M-375.87 M -422.89 M Cash from investing activities -210 K-254 K-197 K-360 K-759 K -201 K Cash from financing activities 383.11 M200.13 M70.89 M472.43 M454.49 M 1.04 B Free cash flow -83.54 M-106.37 M-188.39 M-214.59 M-376.63 M -423.09 M

뉴스

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow (NASDAQ:IMVT) 2026-04-02

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

스티펠, OmniAb에 ’매수’ 등급 재확인…파트너 성장 요인

Stifel reiterates Buy rating on OmniAb stock, cites partner growth

Immunovant stock hits 52-week high at 28.32 USD

[0223시황레이더] 스웨덴 사모펀드 EQT, 더존비즈온 잔여지분 공개매수 등

Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards?

Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?